[1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33.
|
[2] |
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
|
[3] |
Motavaf M, Safari S, Saffari Jourshari M, et al. Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein[J]. Acta Virol, 2013, 57(4):389-396.
|
[4] |
Huang JF, Guo YJ, Zhao CX, et al. Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin[J]. Hepatology, 2013, 57(5):1882-1892.
|
[5] |
Salerno D, Chiodo L, Alfano V, et al. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription[J]. Gut, 2020, 69(11):2016-2024.
|
[6] |
de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2):e180-190.
|
[7] |
Ali A, Abdel-Hafiz H, Suhail M, et al. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(30):10238-10248.
|
[8] |
Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2011, 26 Suppl 1:144-152.
|
[9] |
Matsui M, Corey DR. Non-coding RNAs as drug targets[J]. Nat Rev Drug Discov, 2017, 16(3):167-179.
|
[10] |
Beermann J, Piccoli MT, Viereck J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches[J]. Physiol Rev, 2016, 96(4):1297-1325.
|
[11] |
Liu Y, Feng J, Sun M, et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma[J]. Cancer Lett, 2019(454):158-170.
|
[12] |
Huang P, Xu Q, Yan Y, et al. HBx/ERα complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis[J]. Oncogene, 2020, 39(18):3774-3789.
|
[13] |
Kapranov P, Cheng J, Dike S, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription[J]. Science, 2007, 316(5830):1484-1488.
|
[14] |
Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?[J]. Cell, 2011, 146(3):353-358.
|
[15] |
Wang Y, Yang L, Chen T, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targetingmiR-194-5p/FOXA1 axis[J]. Mol Cancer, 2019, 18(1):28.
|
[16] |
Wang Y, Liu Z, Yao B, et al. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis[J]. Mol Cancer, 2017, 16(1):123.
|
[17] |
Poliseno L, Salmena L, Zhang J, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology[J]. Nature, 2010, 465(7301):1033-1038.
|
[18] |
Johnsson P, Ackley A, Vidarsdottir L, et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells[J]. Nat Struct Mol Biol, 2013, 20(4):440-446.
|
[19] |
Lorenzen JM, Schauerte C, Hübner A, et al. Osteopontin is indispensible for AP1-mediated angiotensinⅡ-related miR-21transcription during cardiac fibrosis[J]. Eur Heart J, 2015, 36(32):2184-2196.
|
[20] |
Darido C, Georgy SR, Wilanowski T, et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis[J]. Cancer Cell, 2011, 20(5):635-648.
|